^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Beromun (tasonermin)

    i
    Other names: FK 516, Recombinant human TNF-α, rhTNF-α
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim
    Drug class:
    TNFα stimulant
    Related drugs:
    Associations

    News

    Trials
    12d
    Hyperthermic isolated limb perfusion with TNF-alpha and melphalan for the treatment of locally advanced soft-tissue sarcoma (PubMed, Oper Orthop Traumatol)
    Perfusion of the limb with 1-2 mg recombinant TNF-alpha (Tasonermin/Beromun, Belpharma SA, Luxembourg) for 15 min, followed by the addition of 11-13 mg melphalan per liter of limb volume and subsequent perfusion for an additional 60 min. Complete remissions observed in just under 20% of cases. Limb preservation is possible in over 80% of cases.
    Review • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    melphalan • Beromun (tasonermin)
    2years
    NivoILP: Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion (clinicaltrials.gov)
    P1/2, N=74, Recruiting, Sahlgrenska University Hospital, Sweden | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Beromun (tasonermin)